Skin in the Game: Tackling Atopic Dermatitis with Topical Treatment - Episode 3
New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
Panelists discuss recent topical atopic dermatitis therapies, which include roflumilast (PDE4 inhibitor, age ≥ 6 years), ruxolitinib (JAK inhibitor, age ≥ 12 years), and tapinarof (hydrocarbon receptor agonist, age ≥ 2 years). Treatment selection considers disease severity, age, affected areas, comorbidities, and previous therapy responses.
Video content above is prompted by the following:
- There have been several new topical therapies approved in recent years. Discuss these treatments, how they work to treat atopic dermatitis, as well as an overview of efficacy and safety data.
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- PDE4 inhibitor; INTEGUMENT-1 and INTEGUMENT-2
- Topical ruxolitinib (1.5% cream): FDA approved for patients 12 years or older
- JAK inhibitor; TRuE-AD1 and TRuE-AD2
- Topical tapinarof (1% cream): FDA approved for patients 2 years or older
- Hydrocarbon receptor agonist; ADORING 1 and ADORING 2
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- What patient factors do you consider when selecting a treatment option?
- How do you decide among all the available topical treatment options for your patients?
